Loading articles...
Serum Potassium Concentrations Shape Heart Failure Risk
Optimal serum potassium concentrations in heart failure (HF) are unclear, with new data clarifying the safe range for HFrEF and HFpEF.
Managing Acute Heart Failure And Cardiogenic Shock
Acute decompensated heart failure drives over one million hospital admissions annually. 30-day readmission rates are 25%. When the heart cannot compensate, the tools change entirely - IV diuretics, inotropes, mechanical circulatory support. Sarah Mitchell a...
Semaglutide For Obese Heart Failure Patients
More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating th...
Diabetes Drugs For Stiff Heart Failure
Heart failure with preserved ejection fraction accounts for more than half of all HF diagnoses. For two decades every major drug trial failed. Then SGLT2 inhibitors changed everything - twice. Sarah Mitchell and James Carter explain why HFpEF was so hard, a...
How Four Drugs Beat Heart Failure
Four drug classes — ARNi, beta-blocker, MRA, SGLT2 inhibitor — have together produced a 73% reduction in cardiovascular death and hospitalisation versus placebo in HFrEF. Sarah Mitchell and James Carter unpack why each drug works, what the landmark trials s...
Tricuspid Valve Surgery Benefits Adults with Systemic Right Ventricle
Adults with transposition of the great arteries (TGA) and systemic morphologic right ventricle (SRV) often develop SRV failure and tricuspid regurgitation (TR). A new study investigates the impact of tricuspid valve surgery (TVS) on clinical outcomes in thi...
PAHO's HEARTS 2.0 Outlines 38-Step Pathway for Cardio-Renal Care
The PAHO HEARTS 2.0 initiative provides a 38-step pathway for integrated cardio-renal care, addressing the complex interplay of cardiovascular and kidney diseases.
Right Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
ATS 2026 session addresses persistent challenges in right heart catheterization waveform interpretation, offering a structured approach to reduce diagnostic ambiguity.
SGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
SGLT2 Inhibitors Post-Heart Transplant: What the Data Show
A 2026 meta-analysis examines SGLT2 inhibitor use in diabetic heart transplant recipients, a population where evidence has been thin and stakes are high.